National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 5 of 5 Research Studies DisplayedMaloney MH, Payne SR, Herrin J
Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice.
Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a central role in the management of neovascular age-related macular degeneration (nAMD), diabetic retinal disease (DRD), and retinal venous occlusive disease (RVO). The goal of this study was to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept in real-world practice. The investigators observed no differences in the risk of acute MI, CVD, major bleeding, or all-cause hospitalization after treatment initiation with intravitreal bevacizumab, ranibizumab, or aflibercept during routine clinical practice.
AHRQ-funded; HS024075; HS025164; HS025402; HS025517; HS026379.
Citation: Maloney MH, Payne SR, Herrin J .
Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice.
Ophthalmology 2021 Mar;128(3):417-24. doi: 10.1016/j.ophtha.2020.07.062..
Keywords: Eye Disease and Health, Medication, Risk, Adverse Drug Events (ADE), Adverse Events
Gopal AD, Wallach JD, Shah SA
On-label and off-label clinical studies of FDA-approved ophthalmic therapeutics.
The authors characterized the frequency, accrual, and quality of on-label and off-label prospective studies of novel FDA-approved ophthalmic therapeutics. They concluded that ophthalmologists should recognize that, for some therapeutics, prospective data guiding off-label use may be limited; expanding post-approval evaluation of FDA-approved and off-label indications may mitigate uncertainties and aid ophthalmologists in optimally assessing the decision to adopt approved therapeutics for off-label use.
AHRQ-funded; HS025164; HS022882.
Citation: Gopal AD, Wallach JD, Shah SA .
On-label and off-label clinical studies of FDA-approved ophthalmic therapeutics.
Ophthalmology 2021 Feb;128(2):332-34. doi: 10.1016/j.ophtha.2020.07.028..
Keywords: Medication, Eye Disease and Health
Slota C, Davis SA, Blalock SJ
Patient-physician communication on medication cost during glaucoma visits.
The aim of this secondary analysis was to describe the frequency and nature of patient-physician communication regarding medication cost during glaucoma office visits. Most participants did not discuss medication cost during their glaucoma office visit. The majority of the subjects who discussed cost had mild disease severity (51 percent), took one glaucoma medication (63 percent), and had Medicare (49 percent) as well as a form of prescription insurance (78 percent).
AHRQ-funded; HS023054.
Citation: Slota C, Davis SA, Blalock SJ .
Patient-physician communication on medication cost during glaucoma visits.
Optom Vis Sci 2017 Dec;94(12):1095-101. doi: 10.1097/opx.0000000000001139.
.
.
Keywords: Eye Disease and Health, Healthcare Costs, Medication, Patient and Family Engagement, Clinician-Patient Communication
Slota C, Sayner R, Vitko M
Glaucoma patient expression of medication problems and nonadherence.
The purpose of this article was to evaluate what patient characteristics led patients to express (1) medication problems, including difficulty with side effects and eye drop administration, and (2) problems with nonadherence to glaucoma medications. It found that patients with lower health literacy are less likely to express medication-related problems and patients who express medication problems often express nonadherence.
AHRQ-funded; HS023054.
Citation: Slota C, Sayner R, Vitko M .
Glaucoma patient expression of medication problems and nonadherence.
Optom Vis Sci 2015 May;92(5):537-43. doi: 10.1097/opx.0000000000000574..
Keywords: Eye Disease and Health, Patient Adherence/Compliance, Medication, Health Literacy
Pershing S, Pal Chee C, Asch SM
Treating age-related macular degeneration: comparing the use of two drugs among Medicare and Veterans Affairs populations.
The researchers examined the diffusion of new biologics ranibizumab and bevacizumab, both for the treatment of macular degeneration but differing in price, in fee-for-service Medicare and Veterans Affairs (VA) systems during 2005-11, in part to assess the impact that differing financial incentives had on prescribing. Their analysis indicated that there are opportunities in both the VA and Medicare to adopt more value-conscious treatment patterns and that multiple mechanisms exist to influence utilization.
AHRQ-funded; HS018434.
Citation: Pershing S, Pal Chee C, Asch SM .
Treating age-related macular degeneration: comparing the use of two drugs among Medicare and Veterans Affairs populations.
Health Aff 2015 Feb;34(2):229-38. doi: 10.1377/hlthaff.2014.1032.
.
.
Keywords: Healthcare Costs, Eye Disease and Health, Medicare, Medication